reading time

GDR Share Price

In response to the COVID-19 pandemic, Genedrive developed and launched its Genedrive® 96 SARS-CoV-2 Kit, a high-throughput molecular diagnostic test for COVID-19. In September 2021, the company announced that it had received CE-IVD marking for the test, allowing it to be sold in the European Economic Area.

In addition to its COVID-19 test, Genedrive has a pipeline of products for other infectious diseases, including hepatitis C and tuberculosis. The company has also announced partnerships and collaborations with other organizations to develop and commercialize its diagnostic technology.

GDR Share Price

The London Stock Exchange listed GenDrive PLC as a publicly traded biotechnology company. The company focuses on developing gene editing technologies to combat diseases. Their flagship product is the “GeneDrive,” a genetic engineering technique that can spread specific genes throughout a population. The GDR Share Price as of this post is at 33.25 GBp.

Various factors, including market trends, news and announcements related to the company, and the biotech sector’s overall performance, may influence GenDrive PLC’s performance in the stock market. Therefore, conducting thorough research and analysis is essential before making investment decisions.

Brief Background on GDR Share

GenDrive PLC is a UK-based biotechnology company that was founded in 2013. The company spun out of the University of Edinburgh’s School of Biological Sciences.

Initially, GenDrive’s research focused on developing a portable diagnostic device for rapidly detecting infectious diseases like Ebola and Hepatitis C. Then, in 2015, the company received a grant from the Bill and Melinda Gates Foundation to develop a diagnostic test for detecting the Zika virus.

In 2018, GenDrive announced the development of its flagship product, the “GeneDrive,” a genetic engineering technique that can spread specific genes throughout a population. The company has focused on using the GeneDrive technology to combat diseases such as malaria and dengue fever.

Since going public in 2017, GenDrive has continued to advance its technology and expand its portfolio of products. In 2020, the company received emergency use authorization from the US Food and Drug Administration (FDA) for its COVID-19 testing kit, which uses its molecular diagnostic platform.

Overall, GenDrive PLC has a relatively short history but has achieved significant milestones in developing innovative biotechnology products for diagnosing and treating infectious diseases.

Advantages of Investing in GDR Share

Genedrive’s core technology is a point-of-care diagnostic platform that enables rapid and accurate diagnosis of infectious diseases, including COVID-19. Some potential advantages of investing in Genedrive PLC may include the following:

  1. Growing demand for rapid diagnostic tests. As the world becomes more connected, the demand for rapid and accurate diagnostic tests for infectious diseases is increasing. Genedrive’s platform is designed to deliver results quickly, which could make it attractive to healthcare providers.
  2. Strong partnerships and collaborations. Genedrive has partnerships with several high-profile organizations, including the Liverpool School of Tropical Medicine and the Foundation for Innovative New Diagnostics (FIND). These collaborations could help Genedrive gain access to new markets and increase the adoption of its technology.
  3. Innovative technology. Genedrive’s platform is based on proprietary technology that has the potential to transform the way infectious diseases are diagnosed and managed. If the company can continue to develop its technology and expand its product offerings, it may be well-positioned to capture a significant share of the molecular diagnostics market.

Main Competitors of Genedrive PLC

Genedrive PLC operates in the molecular diagnostics industry, a highly competitive field with several established players. Some of Genedrive’s main competitors in this industry include:

  1. Roche Diagnostics. A global leader in molecular diagnostics with a broad range of products and services for infectious diseases, oncology, and other areas.
  2. Abbott Laboratories. Another major player in molecular diagnostics that offers a wide range of products and services for infectious diseases, oncology, and other areas.
  3. Cepheid. A leading provider of molecular diagnostics systems and assays focusing on infectious diseases.
  4. Hologic. Hologic provides diagnostic products and services for women’s health, including molecular diagnostic assays for infectious diseases.
  5. BioMérieux. A global leader in microbiology testing and molecular diagnostics, with a broad portfolio of products and services for infectious diseases.

These companies are just a few of the major players in the molecular diagnostics industry, and there are many other competitors that Genedrive may encounter in specific markets or regions.

The Best Copytrading Platform

eToro UK
Minimum deposit 200 USD
Regulated in Europe
Trade selections Forex, Crypto, Stocks, Commodities, ETFs, Indices
  • Zero Commissions on Trades

  • CopyPortfolios/Copytrade Feature

  • Ask Experts Questions

  • Wide Range of Stocks


In its financial reports, Genedrive has reported growing revenue and increasing sales of its diagnostic products. However, the company has also reported net losses in recent years as it invests in research and development and expands its product offerings.


FAQ: GDR Share Price

What is the historic performance of GDR Stock?

Genedrive PLC (ticker symbol: GDR) is a publicly traded company listed on the AIM market of the London Stock Exchange. The company's stock was first listed on AIM in 2013, and since then, its stock price has experienced significant fluctuations, as is typical of small-cap stocks.

Between 2013 and early 2020, GDR's stock price generally traded around 20 to 40 pence per share, with some volatility in response to news and market conditions. However, in early 2020, GDR's stock price surged as the company announced the development of a molecular diagnostic test for COVID-19. As a result, the stock reached a high of over 150 pence per share in March 2020 before gradually declining over the rest of the year.

Since then, GDR's stock price has fluctuated in response to news and market conditions, although it has generally remained above its pre-COVID levels.

Does GDR pay dividends to its stockholders?

Genedrive PLC (GDR) has not historically paid dividends to its stockholders. The company has prioritized investing in research and development and expanding its product offerings over returning profits to shareholders through dividends.

How much does GDR make in a year?

In its latest full-year financial report for June 30, 2021, Genedrive reported total revenues of £4.4 million, up from £2.4 million in the previous year. The increase in revenue was primarily driven by sales of the Genedrive 96 SARS-CoV-2 Kit, which the company developed in response to the COVID-19 pandemic.

Genedrive also reported a net loss of £7.3 million for the year ended June 30, 2021, which was a significant increase from the net loss of £3.7 million in the previous year. The increase in net loss was primarily due to increased investments in research and development and the expansion of the company's product portfolio.

Rate this post
Simon Williams
Latest posts by Simon Williams (see all)